Gillian A. Horne - Concepedia

Author

Gillian A. Horne

University of Glasgow ORCID

Also Known As

G A Horne, G. A. Horne, G. Horne, Gillian A Horne, Gillian A. Horne, Gillian Abigail Horne, Gillian Horne

Publications

996

Citations

H-Index

Concepts

All Affiliations

University of Glasgow University of Liverpool Imperial College London Brighton and Sussex Medical School University of Sussex

About

Gillian A. Horne is an author at University of Glasgow specializing in medicine, cancer research, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	286
2	Cell Biology	2	2	69
3	Natural Sciences	1	1	56
4	Immunology	1	1	31
5	Orthopaedics	1	1	60

Gillian A. Horne

Publications

637

Citations

H-Index

Page 1

	Year	Citations
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma Christopher I. Jones, Maria V. Zabolotskaya, A. J. King, British Journal of Cancer	2012	134
<scp>BRD</scp>4 associates with p53 in <scp>DNMT</scp>3A‐mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor <scp>JQ</scp>1 Helen Stewart, Gillian A. Horne, Sarah Bastow, Cancer Medicine	2013	86
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease Gillian A. Horne, Jon Stobo, Caroline Kelly, Leukemia Hematological MalignancyResidual DiseaseImatinib Versus ImatinibMedicineChronic Myeloid Leukaemia	2020	75
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy Ross Kinstrie, Gillian A. Horne, Heather Morrison, Leukemia	2020	68
Early Results of Endovascular Treatment of the Thoracic Aorta Using the Valiant Endograft Matt Thompson, S. Ivaz, Nicholas Cheshire, CardioVascular and Interventional Radiology Endovascular TechniqueEndovascular TreatmentComposite AllograftVascular SurgeryThoracic Aorta	2007	60
Nanog Requires BRD4 to Maintain Murine Embryonic Stem Cell Pluripotency and Is Suppressed by Bromodomain Inhibitor JQ1 Together with Lefty1 Gillian A. Horne, Helen Stewart, Jacqueline Dickson, Stem Cells and Development Histone ModificationsEpigenetic ChangeNanog Requires Brd4Stem Cell BiologyEpigenetics	2014	56
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial Mhairi Copland, Daniel Slade, Graham McIlroy, The Lancet Haematology Phase 1/2Hematological MalignancyOncologyMedicineHematology	2021	51
Control of an outbreak of respiratory syncytial virus infection in immunocompromized adults B. Jones, Sherry Clark, Evonne T Curran, Journal of Hospital Infection VaccinationImmunocompromized AdultsViral PersistenceRespiratory DiseasesRespiratory Complications	2000	31
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Journal of Clinical Oncology	2024	31
Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells Salihanur Darici, Manuela Zavatti, Luca Braglia, Advances in Biological Regulation Tumor BiologyOncogenic AgentMedicineApoptosisPharmacology	2021	13

Page 1